Lupin gains on its arm launching generic Aciphex Delayed-Release tablets, 20 mg in the US

Lupin’s - US subsidiary, Lupin Pharmaceuticals, has launched its generic Rabeprazole Sodium delayed‐release tablets, 20mg. The company had earlier received final approval from the US FDA for the same. Lupin’s Rabeprazole Sodium delayed‐release tablets, 20mg, are the generic equivalent of Eisai Inc.’s Aciphex delayed‐release tablets, 20mg, and are indicated for the treatment of Gastro esophageal reflux disease (GERD). Aciphex delayed‐release tablets, 20mg, had annual U.S sales of approximately $ 864.3million (IMS MAT Jun 2013).

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.